LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis.Am J Gastroenterol已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。 | PMID 40071779PMC12662148 | 2025-Dec-01 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 无 KM 图 |
| Randomized trial of anti-thymocyte globulin plus lowdose post-transplant cyclophosphamide to prevent graft-versus- host disease in haploidentical transplantation.Haematologica | PMID 40534493PMC12666268 | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| IMPACT OF THE DEXAMETHASONE IMPLANT ON SLOWING DIABETIC RETINOPATHY PROGRESSION: Post Hoc Analysis of the MEAD Study.Retina疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40712145无 PMCID | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图;Figure 3::AI 判定为 other。 | PMID 40712984PMC12833922 | 2025-Dec-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1.AIDS入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40779489PMC12629108 | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLIANCE Study.J Acquir Immune Defic SyndrPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40857111无 PMCID | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The effect of combining lidocaine and ropivacaine on the duration and onset time of an ultrasound-guided infraclavicular brachial plexus nerve block: A randomised controlled trial.Eur J AnaesthesiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40859881无 PMCID | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.JAMA Neurol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 41082199PMC12687091 | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial.JAMA OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41100113PMC12532030 | 2025-Dec-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.Am J PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41320817无 PMCID | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clindamycin Phosphate 1.2%/Adapalene 0.15%/ Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: A Pooled Analysis by Age.J Drugs DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41329145无 PMCID | 2025-Dec-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.Expert Rev VaccinesPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39720838无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.J Dermatolog TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39799945无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.Hum Vaccin Immunother已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 39836458PMC12934188 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies.Hum Vaccin ImmunotherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39840832PMC12934126 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China.Hum Vaccin Immunother已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram。 | PMID 39895085PMC11792797 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial.J Dermatolog TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39900352无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China.Expert Rev VaccinesPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 39916494无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.Emerg Microbes Infect疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:AI 判定为 other;Figure 3.:非 KM 图。 | PMID 39998495PMC11894744 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of fixed-dose clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel in Hispanic participants with moderate-to-severe acne: a pooled analysis.J Dermatolog Treat入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40122140无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.Hum Vaccin Immunother疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:非 KM 图;Figure 3.:ROC 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图。 | PMID 40174609PMC11970786 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study.Expert Rev VaccinesPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40195167无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40263079无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.Eur J Psychotraumatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图。 | PMID 40331914PMC12064107 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.Hum Vaccin Immunother | PMID 40376714PMC12087488 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.Arthritis Rheumatol已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。 | PMID 40417858PMC12750125 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis.Arthritis Rheumatol已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。 | PMID 40420438PMC12750129 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Comparative immune response of Typbar TCV® (typhoid conjugate vaccine) in extremes of age: An Indian experience.Hum Vaccin Immunother入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40445123PMC12128665 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Dostarlimab and niraparib in primary advanced ovarian cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40461381无 PMCID | 2025-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration.Ophthalmol RetinaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40466770无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.Eur J Heart Fail | PMID 40488446PMC12803551 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Immune persistence of a single dose of 23-valent pneumococcal polysaccharide vaccine: A 6-year follow-up.Hum Vaccin Immunother已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。 | PMID 40537903PMC12184158 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection.Gut Microbes已检查 10 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 5 张未列出。 | PMID 40552763PMC12931727 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.Clin Pharmacol Ther已检查 5 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:身体组成变化图;Figure 3:身体组成变化图;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other。 | PMID 40556483PMC12641085 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Randomized Controlled Trial of Silver Diamine Fluoride Application Time.J Dent Res入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40583169PMC12612282 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Prophylactic Versus Reactive (PvR) Feeding in Patients Undergoing (Chemo)radiation in Head and Neck Cancers: Results of a Phase III Randomized Controlled Trial.Head Neck | PMID 40662454PMC12617468 | 2025-Dec | 0.85 | The study is a Phase III randomized trial in human oncology, but it evaluates a non-drug intervention (prophylactic vs. reactive enteral feeding) and its primary endpoint is weight loss incidence, not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the inclusion criteria for a drug-containing intervention with a time-to-event endpoint. | 已完成 |
| Swallowing and Communication Outcomes Post Chemoradiotherapy for Low-Risk Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma: A Substudy of TROG 12.01.Head NeckPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40662470无 PMCID | 2025-Dec | 0.95 | The record is from a Phase III randomized trial with a drug intervention (chemotherapy) for oncology, but the reported outcomes are not time-to-event efficacy endpoints (OS, PFS, DFS, etc.). The study assesses swallowing and communication outcomes, which are functional or quality-of-life measures, not the required primary/key secondary survival endpoints. | 无 KM 图 |
| Efficacy and safety of moxidectin-albendazole combination therapy for Trichuris trichiura infections in school-aged children: a double-blind, randomised, controlled, superiority trial.Lancet Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40675166无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.Lancet Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40675167无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial.Lancet Infect Dis入排复审未纳入:The study is a non-randomized trial with an immunobridging endpoint (antibody concentrations) as the primary outcome, not a time-to-event efficacy endpoint like OS or PFS. | PMID 40683285PMC12630073 | 2025-Dec | 0.95 | The study is a non-randomized trial with an immunobridging endpoint (antibody concentrations) as the primary outcome, not a time-to-event efficacy endpoint like OS or PFS. | 无 KM 图 |
| Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis.Am J TransplantPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40701254无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies.Aliment Pharmacol Ther已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 forest plot。 | PMID 40704461PMC12646624 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40706710无 PMCID | 2025-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| A Hybrid Design Incorporating External Data to Evaluate Dexamethasone Intracameral Drug Delivery Suspension for Post-Cataract Surgery Inflammation.Clin Pharmacol Ther入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40745864无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.Am J Obstet GynecolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40752754无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52).J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40784561无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Population Pharmacokinetic and Exposure-Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management.J Clin Pharmacol已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other。 | PMID 40796529PMC12649288 | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Use of a Personalised Early Warning Decision Support System for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the "Predict & Prevent" Phase III Trial.COPDPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40799048无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40846240无 PMCID | 2025-Dec | 0.90 | The study meets most criteria (oncology, human, randomized, Phase III, original result), but lacks a time-to-event primary or key secondary efficacy endpoint. The efficacy endpoints are histological and clinical clearance rates at a fixed timepoint, not time-to-event outcomes such as OS, PFS, DFS, or those analyzed via Kaplan-Meier/HR. | 无 KM 图 |
| Palonosetron Plus Megestrol Acetate Versus Palonosetron Plus Dexamethasone in Preventing Moderately Emetogenic Chemotherapy-induced Nausea and Vomiting: A Randomized, Multicenter, Crossover Trial.J Pain Symptom Manage入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40876663无 PMCID | 2025-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |